Thanks, Paul. And once again, thank you all for joining our webcast this afternoon. We have achieved a multitude of important milestones during the second quarter and current period, strengthening our position as a market leader with our integrated portfolio of proven products and services that manage and treat obesity and associated metabolic diseases. Our recently announced FDA 510(k) clearance for the disposable gastrointestinal balloon indicator, calibration tube is a significant milestone for the company. We expect this line extension of calibration tubes to be rapidly adopted by surgeons given their ability to help better visualize the anatomy, making it easier to identify potential defects during a broad range of bariatric procedures such as laparoscopic sleeve gastrectomy, gastric bypass and adjustable gastro banding. We look forward to formally introducing this new important product at the International Federation for surgery of obesity and metabolic disorders, World Congress in Miami later this month and expect to commercial sales to begin in September. Our partnership with OpenLoop, an expert in full stack virtual care delivery services provides a nationwide physician-led telehealth solution for reshapecare, which vastly extend the reach of our proprietary digital therapeutic weight loss and wellness program. It is important to note, reshapecare is a doctor prescribed and may be covered by insurance for up to 26 visits for reimbursement year, making it an effective and convenient virtual health coaching programs. In partnership with physicians, the program is differentiated by the current virtual weight loss market through live video-based counseling with doctors and board-certified health coaches, to ensure the most comprehensive and customized care possible, including implementing behavioral change to improve sleep nutrition exercise in stretch levels. reshapecare is appropriate for all weight loss patients, including medical weight loss and pre and postsurgical bariatric patients. As a result, we are able to tap into the virtual health care delivery space, a market that is expected to reach $95 billion by 2026. Specifically, the rollout of reshapecare and its extension ReShape Marketplace, which includes advanced line of premium supplements allows ReShape to distinguish itself as an incredibly valuable e-commerce platform of health care provider recommended competitively priced weight loss and wellness products for bariatric surgery and medical weight loss patients that support nutrition exercise, sleep and stress. We remain encouraged by the continued pace of inbound requests from bariatric surgeons for refresher courses on the Lap-Band Program. In fact, this year, dozens of bariatric surgeons have approached us for recertification, which is an acknowledgment of the growing patient demand and established safety and efficacy of the anatomy sparing Lap-Band procedure. Keep in mind that this is additive to our existing accounts, and we are receiving a steady flow of requests for refresher courses every week. As we previously noted, we would again like to congratulate Vern Vincent, our Global Director for Clinical training, the ASMBS 2022 distinguished Industry Partner Award, who is leading the retraining effort and facilitating the training of the next generation of bariatric surgeons, including for the first time, bariatric fellows. on the benefits of the Lap-Band during the session at the ASMBS annual conference this past June. As a result of this renewed interest, the Lap-Band from industry groups such as ASMBS, our focus has been on both reengagement of accounts that have historically used the Lap-Band and bringing in new accounts, especially within the underserved major markets. Doctors are realizing that Lap-Band can be additive to their practices and that is not taking away any business from more aggressive stapling and gastric bypass procedures. We are creating a whole new market for people who don't want those procedures that may be giving up on diets. We are enthusiastic about this trend and expect a steady stream of practices to request training going forward buoyed by our multi-platform DTC advertising campaign, which continues to drive patient engagement. The anatomy sparing Lap-Band is unrivaled in the market, and it is adjustable, reversible and well-proven with over 1 million bands having been placed in patients globally in the last 20 years, demonstrating an incomparable safety profile compared to highly aggressive stomach stapling procedures and diets. Adjustability, reversibility and having personal control are all highly desirable aspects for potential patients when making bariatric surgery decisions. Additionally, the reduced risk of adverse events and nutritional deficiencies, associated with anatomy-altering procedures have also been identified as being of great significance in this decision-making process. The fact that most patients return home the same day as their Lap-Band procedure, which is available in outpatient surgery centers is also a key determining factor in the weight loss procedure decisions. As a reminder, our multi-tiered DTC marketing campaign has utilized strategically placed national television print and now to a greater extent, targeted digital media in order to market our Lap-Band program with available after care supported to reshapecare. From the outset of the campaign, we have leveraged the highest viewed television channel and printed publications with the goal of effectively communicating the benefits and differentiated advantages of the Lap-Band, which have been featured in over 15 major magazine publications, including people, good housekeeping, better homes and gardens and over 28 national stations, including Bravo, Lifetime USA and A&E and Hallmark, all of which focus on our target audience. We continue to improve on these marketing efforts through diligent metric analysis and adaptation while also incorporating co-op marketing partnerships, local digital media and national social media influencer campaign. We have been successful in creating and building customer engagement, which has led to increased patient demand for the Lap-Band Program, which has then led to the filling of bariatric surgeons pipelines. Today, we can track customer engagement, leads and warm [ph] transfers of qualified patients, to practices with a high level of confidence. Based on tracking these metrics, we have been able to adapt our DTC marketing campaign to be more effective and more efficient. This will all lead to increased Lap-Band procedures and thus potentially a significant increase in revenues for ReShape Lifesciences over time. The results of this campaign have been overwhelmingly positive so far indicating that our message is clearly resonating with the consumer and professional markets. In fact, doctors were working hard to catch up from the demand backlog that the marketing campaign created while surgery centers were shut down. The typical 6-month mandatory waiting period imposed by insurers creates a lag between early engagement and actual procedures. This means that after we transfer a warm lead to a doctor from our DTC campaign, insurers will require a patient to go through several steps, which may include behavioral analysis, physical analysis or perhaps trying a medically managed weight loss program one more time to make sure they can't lose weight that way and need surgery. This represents a lag between the preliminary investment towards our marketing efforts, initial patient engagement and scheduled procedures. As these scheduled procedures are starting to flow, we are really excited what the next few quarters could look like based on the metrics we are tracking from the DTC campaign. We are now just starting to reap the benefits of this strategic outreach, and we are optimistic that revenue will continue to increase through the remainder of '22 and beyond. Turning to a review of our financial performance. A full discussion of our financials is available in our press release and 10-Q. So I will just take a moment to review key financials for the second quarter ended June 30, 2022. Our revenue totaled $2.9 million for the 3 months ended June 30, 2022, which represents a contraction of 18.1% versus the same period in 2021. As I explained earlier, the primary reason for this decline is the COVID-19 Omicron variant, which caused a significant number of bariatric centers to close in January, February and into March 2022. As a spread of the Omicron variant began to subside, we were pleased to have experienced a 19% increase in sequential revenues compared to the first quarter. As I noted in my prior remarks, we expect sales to continue to increase through the remainder of 2022, as we have witnessed continued growth in patient engagement and doctor consultations attributable to our DTC marketing campaign. We reported gross profit of $1.9 million compared to $2.2 million for the 3 months ended June 30, 2021, Gross profit as a percentage of total revenue for the 3 months ended June 30, 2022, was 65.1%, a solid improvement compared to 61% for the same period in 2021. The gross profit margin increased during the 3 months ended June 30, 2022, primarily due to the company at a higher percentage of domestic sales than in the same period of 2021, which has a higher gross profit margin than international sales. Sales and marketing expenses for the 3 months ended June 30, 2022, increased to $4.7 million compared to $1.4 million for the same period in 2021. The increase is primarily due to an increase in advertising and marketing costs of $1.8 million after having launched the DTC marketing campaign during the fourth quarter of 2021 and expanding this campaign during the first half of 2022. There were also increases related to strengthening the commercial organization and increase in consulting and professional fees related to the launching of the digital media platform, as well as other smaller increases such as travel-related expenses as markets began to open up again. General and administrative expenses for the 3 months ended June 30, 2022, increased to $5.4 million compared to $4.3 million for the same period in 2021. The increase is primarily due to $2 million of legal expenses and increases in stock-based compensation of $1.2 million and an increase in payroll expense as we continue to make strategic organization changes. This was offset by a decline of $2.3 million in consulting and other professional fees that the company has significant related costs during the second quarter of 2021 due to the merger with Obalon. Research and development expenses were $800,000 for the 3 months ended June 30, 2022, compared to $100,000 for the same period in 2021. The increase is due to an increase related to consulting fees and an increase in payroll expenses, including stock-based compensation. On a non-GAAP adjusted EBITDA basis, the loss of $7.8 million for the 3 months ended June 30, 2022, compared to a loss of $1.2 million for the same period last year. It is important to note that revenues were delayed due to the mandatory wait period of approximately 6 months for insurance verification purposes, which we previously discussed. The increased loss is primarily due to the previously mentioned increase in advertising and marketing costs from the DTC marketing campaign, a related increase in payroll expenses due to the expansion of the commercial team, an increase in stock-based compensation and an increase in legal expenses. Lastly, during the quarter, we continued to strengthen our balance sheet, grossing $2.5 million in proceeds from warrant exercise after having eliminated all debt previously from our balance sheet at the end of last year. We ended the quarter with $11.5 million in cash and cash equivalents, which combined with an increase in revenues for the second half of 2022 and beyond should extend our cash runway well into 2023. With that, I will now turn the call back over to Paul.